SK Hynix, Intel Discuss U.S. Memory Chip Production Deal 
Databricks to Invest $350 Million in Singapore AI Expansion 
OpenAI Rejects Apple Trade Secret Theft Claims 
Nvidia CEO Jensen Huang Expected at Trump-Xi State Dinner 
Ex-Google DeepMind Researcher Warns AI Could Pose Existential Threat 
SEC Seeks ISS Client Voting Records in Proxy Adviser Probe 
OpenAI Rules Out 2026 IPO as Altman Prioritizes AI Safety 
Ecuador Court Convicts Ex-President Lenin Moreno in Bribery Case 
Cathie Wood Backs AI Slowdown as Safety Concerns Grow 
Prince Harry Faces Potential Multi-Million-Pound Legal Bill in Daily Mail Case 
Brazil Court Suspends Sigma Lithium Mine Operations 
Nvidia Eyes $10 Billion Investment in Anthropic IPO 
SoftBank Shares Plunge 11% After OpenAI Rules Out 2026 IPO 
Honduras Court Drops Charges Against Ex-President Juan Orlando Hernandez 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
29 US states are suing Meta. What might it mean for the rest of the world? 
Add as a preferred source on Google
Texas Attorney General Ken Paxton has filed a lawsuit against pharmaceutical giant Sanofi, accusing the company of unlawfully incentivizing healthcare providers to prescribe its medications instead of competing alternatives. According to the attorney general’s office, Sanofi allegedly created service-based programs for healthcare professionals that effectively functioned as bribes, in violation of the Texas Health Care Program Fraud Prevention Act.
State officials claim these programs were designed to improperly influence prescribing decisions, potentially impacting fair competition and patient care within Texas healthcare programs. The lawsuit seeks more than $1 million in monetary relief, including civil penalties, as well as a court injunction to prevent any further alleged unlawful conduct.
Sanofi has strongly denied the allegations. In a public statement, the company asserted that its services are fully structured to comply with both federal and state regulations. Sanofi emphasized that the programs are intended to support patient care and improve health outcomes, not to sway physicians’ prescribing behavior. The company also stated that the state’s legal action does not reflect the merits of the case and confirmed it will vigorously defend itself in court.
This is not the first time Attorney General Paxton has taken legal action against major pharmaceutical companies. Previously, Texas sued Sanofi and Bristol-Myers Squibb, alleging they failed to disclose that their blood thinner Plavix was less effective for certain patients. In a separate case last year, the state filed a lawsuit against Eli Lilly, accusing the drugmaker of bribing healthcare providers to prescribe its top-selling medications, including GLP-1 drugs Mounjaro and Zepbound.
The latest lawsuit highlights Texas’ continued scrutiny of pharmaceutical industry practices, particularly regarding alleged healthcare fraud, drug marketing tactics, and compliance with state healthcare laws.
